MedTrace Logo

Light-deprivation Utilized to Mitigate Amblyopia

NCT02685423 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2019-08-29

No results posted yet for this study

Summary

Amblyopia is an impairment in spatial vision caused by asymmetry in the quality of visual input across the two eyes during childhood. It is difficult to treat in adulthood because the visual system becomes less "plastic" (able to learn) with age. The purpose of this study is to determine whether five to ten days of visual deprivation--living in complete darkness--can enhance plasticity in the visual cortex and thereby facilitate the learning that is needed to recover visual function in amblyopic adults.

Conditions

  • Amblyopia

Interventions

BEHAVIORAL

Binocular deprivation 10 days

Research participants will be asked to live 10 days in an experimentally-controlled dark environment.

BEHAVIORAL

Vision training

Subjects will play a video game on their VR headset for 24 minutes per day, followed by 20 minutes of binocular experience with a brightness-reducing filter over the non-amblyopic eye.

Sponsors & Collaborators

  • University of Maryland, College Park

    collaborator OTHER

  • Nova Southeastern University

    collaborator OTHER

  • National Eye Institute (NEI)

    collaborator NIH

  • State University of New York College of Optometry

    lead OTHER

Principal Investigators

  • Benjamin T Backus, PhD · Grad Ctr for Vision Research, SUNY College of Optometry

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2019-09-30
Completion
2019-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02685423 on ClinicalTrials.gov